Shelley Hwang, MD, a surgical oncologist at Duke Cancer Institute, recently unveiled groundbreaking results from the COMET study, which suggests a transformative approach for treating early stage breast cancer (DCIS) through watchful waiting and monitoring as a alternative to surgery.
If longer-term data confirm the findings, Hwang will have reached one important summit of her career-long journey, possibly changing the standard of treatment for tens of thousands of women and men diagnosed with DCIS.
Her determination and calculated long-term goal setting mirrors one of her other major passions: mountain climbing.
Dr. Hwang, the Mary and Deryl Hart Distinguished Professor of Surgery at Duke University's School of Medicine, is a well-known advocate for breast cancer research, and her work earned her a place on TIME magazine's list of the 100 Most Influential People in 2016.
Read more about her work on DCIS and climbing here:
https://medschool.duke.edu/stories/reaching-new-heights-cancer-care
If longer-term data confirm the findings, Hwang will have reached one important summit of her career-long journey, possibly changing the standard of treatment for tens of thousands of women and men diagnosed with DCIS.
Her determination and calculated long-term goal setting mirrors one of her other major passions: mountain climbing.
Dr. Hwang, the Mary and Deryl Hart Distinguished Professor of Surgery at Duke University's School of Medicine, is a well-known advocate for breast cancer research, and her work earned her a place on TIME magazine's list of the 100 Most Influential People in 2016.
Read more about her work on DCIS and climbing here:
https://medschool.duke.edu/stories/reaching-new-heights-cancer-care
- Category
- Oncology

Be the first to comment